It’s the industry disruptors, the unusual partnerships, and the cross-border and cross-sector relationships that are driving Collaborative Transformation in the health care and life sciences organizations. But a Collaborative Transformation takes more than signing paperwork and shaking hands. A successful Collaborative Transformation takes cultural integration between non-traditional partners, incorporating new technologies into health care regulatory compliance structures, and so much more. At McDermott, we’ve recently had the opportunity to help our clients pursue their own Collaborative Transformations, and are proud to showcase their achievements.
Innate Pharma Expands its Collaboration with AstraZeneca
McDermott Will & Emery advised Innate Pharma, a French oncology-focused biotech company, in signing a multi-term agreement with AstraZeneca and MedImmune – AstraZeneca’s global biologics research and development arm. This agreement broadens the existing collaboration, aimed at accelerating the development of an oncology portfolio of each of the parties and to provide patients with more rapid access to new therapeutic options. This extended collaboration will permit Innate Pharma to develop and commercially strengthen its investment ability to develop its immuno-oncology portfolio (IO) and its R&D platform. For its part, AstraZeneca will enrich its IO portfolio with new clinical and preclinical programs. For more information on this collaboration, click here.
CVS + Aetna
McDermott is one of the firms that has advised CVS Health in connection with its $69 billion purchase of Aetna. The transaction, one of this year’s largest M&A deals, is expected to transform the US health care sector. For more information on this collaboration, click here.
Precision Spine Care and Roseland Management, LLC Complete Sale to Bow Capital Partners
McDermott Will & Emery represented neurosurgery and pain management medical practice Precision Spine Care and its affiliated practice management company Roseland Management, LLC with respect to a pre-closing restructuring and sale of Roseland Management to Bow River Capital Partners. Physician practice management (PPM) transactions can raise unique regulatory and integration challenges as companies and physicians work together to develop mutually beneficial solutions that adhere to the rigorous regulatory compliance standards PPMs must adhere to. The recapitalization resulted in retained meaningful ownership stake for Precision’s founding physicians, and allows their current management team to continue leading the organization, which serves patients across seven facilities across East Texas. For more information on this collaboration, click here.
Every strategic partnership presents its own challenges and opportunities, but collaborations that that propel the industry forward present complex legal issues that demand creative strategies. The unique legal issues presented by these relationships require a team that understands the science behind the solutions, in addition to the regulatory and transactional complexities that arise when companies work together driving changes. Are you ready to purse your next partnership? Let’s get to work.
